José A. Mira-Escarti-rekin lankidetzan egindako argitalpenak (8)

2014

  1. A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers

    Liver International, Vol. 34, Núm. 4, pp. 558-566

2013

  1. Baseline risk factors for relapse in HIV/HCV co-infected patients treated with PEG-IFN/RBV

    Infection, Vol. 41, Núm. 1, pp. 21-26

  2. Pegylated interferon plus ribavirin is suboptimal inIL28B CC carriers without rapid response

    Journal of Infection, Vol. 67, Núm. 1, pp. 59-64

  3. Short communication: Atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C

    AIDS Research and Human Retroviruses, Vol. 29, Núm. 2, pp. 223-225

2012

  1. Association between the IL28B genotype and hepatitis C viral kinetics in the early days of treatment with pegylated interferon plus ribavirin in HIV/HCV co-infected patients with genotype 1 or 4

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 1, pp. 202-205

2011

  1. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype

    HIV Medicine, Vol. 12, Núm. 8, pp. 487-493

  2. Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV-hepatitis C virus-coinfected patients with prior nonresponse or relapse

    AIDS, Vol. 25, Núm. 8, pp. 1131-1133

2010

  1. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus

    Clinical Infectious Diseases, Vol. 51, Núm. 7, pp. 788-795